KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.96

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.

Lu Xie, Jie Xu, Xin Sun, Kuisheng Liu, Kunkun Sun, Yuan Li, Rong Liu, Du Wang, Shurong Shao, Zhongjiang Chen, Zheng Pang, Guangxin Zhou, Sujia Wu, Yingqi Hua, Haiyan Hu, Ran Wei, Yi Yang, Tao Ji, Wei Guo, Xiaodong Tang

Nat Commun 16(1) 10473

PMID41290609
PMCIDPMC12647724
DOI10.1038/s41467-025-65467-8
发表日期2025-11-25
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This is a phase II randomized controlled trial, not a phase III trial.
摘要

摘要

Relapsed or refractory osteosarcoma carries a poor prognosis after standard chemotherapy. We conducted a multicenter, randomized, phase II trial (NCT05277480) to compare apatinib plus ifosfamide/etoposide (IE) with IE alone in patients who had progressed following at least one prior line of chemotherapy. Patients were randomized 2:1 to receive apatinib (500 mg orally once daily) plus IE (ifosfamide 1.8 g/m²/day and etoposide 100 mg/m²/day, days 1-3 every 3 weeks) or IE alone (same doses, days 1-5 every 3 weeks). The primary endpoint was progression-free survival (PFS). Between April 14, 2022, and August 22, 2023, 81 patients were enrolled (53 in apatinib plus IE group and 28 in IE group). After a median follow-up of 19.9 months, the median PFS was 5.5 months (95% confidence interval [CI]: 3.9, 6.4) with apatinib plus IE compared with 3.4 months (95% CI: 1.4, 4.6) with IE (hazard ratio, 0.60; 95% CI: 0.37, 0.98; P = 0.0402). The trial met its pre-specified primary endpoint. These results suggest that apatinib plus IE may improve PFS in relapsed or refractory osteosarcoma, but as a randomized phase II study, the findings are exploratory and require confirmation in phase III trials.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。